JNJ Johnson & Johnson

267.14USD-2.04%Mkt Cap: 643.09B USDP/E: 40.54

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap643.09B USD
Enterprise Value683.90B USD
Revenue (TTM)99.33B USD
Gross Profit63.94B USD
Net Income (TTM)26.80B USD
Revenue/Share41.25 USD
Last Price267.14 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees138.2K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)40.54
P/E (Forward)23.00
PEG3.07
EV/EBITDA19.82
EV/Revenue6.88
P/S6.47
P/B7.89
EPS (TTM)6.59 USD
EPS (Forward)11.61 USD
52W Range
195.9076% of range290.25
52W High290.25 USD
52W Low195.90 USD
Profitability
Gross Margin67.88%
Oper. Margin26.59%
EBITDA Margin34.73%
Profit Margin28.46%
ROE32.87%
ROA13.46%
ROIC19.25%
ROCE17.64%
Growth
Revenue Growth5.90%
Earnings Growth-95.90%
Cash Flow & Leverage
Operating CF24.53B USD
CapEx (TTM)5.22B USD
FCF Margin18.63%
FCF Yield2.88%
Net Debt27.42B USD
Net Debt/EBITDA0.79
Net Debt/FCF1.48
Balance Sheet
Debt/Equity0.59
Current Ratio1.02
Quick Ratio0.65
Book Value/Sh33.87 USD
Cash/Share7.16 USD
Dividends
Fwd Div Rate5.36 USD
Trail. Div Rate5.28 USD
Div. Yield1.97%
5Y Avg Yield2.66%
Payout Ratio80.12%
Ex-Div DateNov 24, 2026
Pay DateDec 8, 2026
Splits
Last Split2:1
Split DateJun 13, 2001
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)280.18 USD
Upside (mean)+4.9%
Target Range190.00 USD – 320.00 USD
190.00+4.9% to mean320.00
# Analysts22
Ownership
Shares Out.2.41B
Float2.40B
Insiders0.08%
Institutions77.02%
Short Interest
Short Ratio2.2d
Short % Float0.79%
Short % Out.0.71%
Shares Short17.07M
Short (prev mo.)22.07M
Technical
SMA 50267.01 (+0.0%)
SMA 200250.06 (+6.8%)
Beta0.20
S&P 52W Chg12.08%
Avg Vol (30d)7.74M
Avg Vol (10d)7.75M
Technical Indicators
RSI (14)44.6
MACD3.1473
MACD Signal4.1201
MACD Hist.-0.9728
BB Upper287.69 USD
BB Middle274.68 USD
BB Lower261.66 USD
BB Width9.47%
ATR (14)6.703 USD
Vol Ratio (20d)1.33x

About Johnson & Johnson (NYSE: JNJ)

›

Johnson & Johnson (NYSE: JNJ) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 138,200 employees.

The shares were at 267.14 USD on 19 November 2026, up 37.9% over 52 weeks. Its 52-week range is 195.90 USD to 290.25 USD: the price is 8.0% below the high and 36.4% above the low.

At a market capitalisation of 643.09B USD, it trades at 40.5 times trailing earnings and 23.0 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 59% for JNJ. It pays a dividend yielding 1.97% (it pays out 80% of its earnings), against a median of 2.55% among the dividend payers in that peer group.

Johnson & Johnson reports return on equity of 32.9%, an operating margin of 26.6% and revenue up 5.9% year over year.

Its debt exceeds its cash by 27.42B USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 22 analysts cover the stock, with an average rating of Buy; their mean price target of 280.18 USD is 4.9% above the current price. The next earnings report is expected on 26 January 2027.